Acumen Pharmaceuticals, Inc. financial data

Symbol
ABOS on Nasdaq
Location
427 Park St., Charlottesville, VA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 655 % -62%
Debt-to-equity 38.4 % +115%
Return On Equity -97.4 % -195%
Return On Assets -70.4 % -151%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.6M shares +0.82%
Common Stock, Shares, Outstanding 60.6M shares +0.82%
Entity Public Float 97.5M USD -27.3%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.6M shares +0.82%
Weighted Average Number of Shares Outstanding, Diluted 60.6M shares +0.82%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 119M USD +64%
General and Administrative Expense 19.3M USD -5.31%
Operating Income (Loss) -138M USD -48.8%
Nonoperating Income (Expense) 4.88M USD -56.6%
Net Income (Loss) Attributable to Parent -133M USD -63.3%
Earnings Per Share, Basic -2 USD/shares -62%
Earnings Per Share, Diluted -2 USD/shares -62%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46.8M USD +41.1%
Marketable Securities, Current 79.8M USD -52.3%
Other Assets, Current 457K USD +152%
Assets, Current 132M USD -36.4%
Property, Plant and Equipment, Net 115K USD +29.2%
Operating Lease, Right-of-Use Asset 173K USD -41.6%
Other Assets, Noncurrent 393K USD +131%
Assets 142M USD -46.7%
Accounts Payable, Current 682K USD -70.9%
Employee-related Liabilities, Current 2.78M USD +35.2%
Accrued Liabilities, Current 7.79M USD +58.2%
Liabilities, Current 22M USD +10.3%
Operating Lease, Liability, Noncurrent 39K USD -78.9%
Other Liabilities, Noncurrent 39K USD
Liabilities 49M USD -1.46%
Accumulated Other Comprehensive Income (Loss), Net of Tax 109K USD -79%
Retained Earnings (Accumulated Deficit) -421M USD -46.3%
Stockholders' Equity Attributable to Parent 93.2M USD -57.1%
Liabilities and Equity 142M USD -46.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.1M USD -91.1%
Net Cash Provided by (Used in) Financing Activities -36K USD -101%
Net Cash Provided by (Used in) Investing Activities 28.7M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 60.6M shares +0.82%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 47.1M USD +40.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 724K USD -4.23%
Deferred Tax Assets, Valuation Allowance 56.4M USD +67.6%
Deferred Tax Assets, Gross 56.7M USD +66.2%
Operating Lease, Liability 185K USD
Depreciation 15K USD -6.25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -134M USD -65.9%
Lessee, Operating Lease, Liability, to be Paid 388K USD
Operating Lease, Liability, Current 146K USD +13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 158K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 155K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 44K USD +1000%
Lessee, Operating Lease, Liability, to be Paid, Year Three 158K USD
Deferred Tax Assets, Operating Loss Carryforwards 20.9M USD +26.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 38K USD -5%
Additional Paid in Capital 514M USD +1.93%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 273K USD -37.5%
Share-based Payment Arrangement, Expense 9.78M USD +9.52%
Interest Expense 1M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%